CTLA-4 rs231775 and risk of acute renal graft rejection: an updated meta-analysis with trial sequential analysis

Sarah Cargnin1, Ubaldina Galli2, Jae Il Shin3 & Salvatore Terrazzino1*

Contrasting results exist on the association between CTLA-4 rs231775 and acute rejection in kidney transplant recipients. We herein conducted an updated systematic review with meta-analysis and trial sequential analysis (TSA) to clarify this relationship and to establish whether the current evidence is sufficient to draw firm conclusions. In addition, noteworthiness of significant pooled odds ratios (ORs) was estimated by false positive report probability (FPRP). A comprehensive search was performed through PubMed, Web of Knowledge, Cochrane Library and Open Grey up to October 2019. Fifteen independent cohorts, including a total of 5,401 kidney transplant recipients, were identified through the systematic review. Overall, no association was detected with the allelic (OR 1.07, 95% CI 0.88–1.30, P = 0.49), dominant (OR 0.94, 95% CI 0.73–1.22, P = 0.66) or the recessive (OR 1.18, 95% CI 0.97–1.43, P = 0.096) model of CTLA-4 rs231775. In each genetic model, the cumulative Z-curve in TSA crossed the futility boundary and entered the futility area. In addition, none of the significant genetic comparisons detected in the subsequent and sensitivity analyses or in previously reported meta-analyses were found to be noteworthy by FPRP. In conclusion, this study provides strong evidence that CTLA-4 rs231775 is not a clinically-relevant genetic risk determinant of acute rejection after renal transplantation.

Cytotoxic T lymphocyte antigen-4 (CTLA-4, also known as CD152) is a transmembrane homodimer glycoprotein expressed by activated effector T cells (Teffs) that negatively regulates T cell-mediated immune responses1. CTLA-4 exerts its immunosuppressive function through a variety of mechanisms which include competition with the co-stimulatory CD28 molecule for binding to their shared B7 ligands (CD80/CD86) on the antigen-presenting cells (APC)2, and interference with TCR-mediated signal transduction3. Given the key role of CTLA4 in regulation of allograft rejection and tolerance4,5, a great attention has been focused on the relationship between CTLA-4 genetic variation and graft outcome following solid organ transplantation6–9.

The human CTLA-4 gene is located on the short arm of the second chromosome (2q33) and consists of four exons encoding respectively the leader sequence peptide, an extracellular immunoglobulin like domain containing the binding site, a transmembrane domain and a cytoplasmic tail10,11. The single-nucleotide polymorphism (SNP) rs231775 of the CTLA-4 gene, also referred as +49A>G, causes a threonine-to-alanine substitution at codon 17 in the peptide leader sequence, and guanine at this position is related to reduced CTLA-4 protein expression12. Over the last fifteen years, several efforts have been made to evaluate the impact of CTLA-4 rs231775 on the risk of acute rejection in kidney transplant recipients, however the results differed among studies, which reported a lack of association13,14 or a higher risk of acute renal rejection among GG carriers15,16 or inconclusive findings because of low sample size17–19. The reasons for these conflicting and inconclusive results may be the different ethnicity, the clinical heterogeneity, the low statistical power or a combination of these factors.

Up to now, six meta-analyses have been conducted to clarify the role of CTLA-4 rs231775 on the risk of acute renal graft rejection20–25. However, all these studies did not take into account the risk of random errors due to
sparse data and multiple meta-analytic up-dates\textsuperscript{26,27}, which often result in false positive (type-1 error) and false negative (type-2 error) findings. Given that the above-mentioned issues can be addressed by application of trial sequential analysis (TSA) to meta-analytic results\textsuperscript{28} and the recent publication of two novel primary studies\textsuperscript{29,30}, we herein conducted an updated meta-analysis with TSA to assess reliability of the accumulated evidence on the relationship between CTLA-4 rs231775 and acute renal transplant rejection. In addition, noteworthiness of significant pooled estimates from the present and previous meta-analyses was estimated by false positive report probability (FPRP).

Materials and methods

Literature search and selection criteria. This systematic review was conducted in accordance with the PRISMA Statement principles\textsuperscript{31}. A computerized literature search was carried out on PubMed, Web of Knowledge, Cochrane Library and Open Grey (last search up October 17th, 2019) by using the Boolean combinations of the key terms: (cytotoxic T-lymphocyte antigen 4 OR CTLA4 OR CTLA-4 OR GWAS OR genome-wide association study) AND (polymorphism OR polymorphisms OR SNP OR SNPs OR genotype OR genotypes OR allele OR alleles OR variant OR variants) AND (kidney OR renal) AND rejection. Eligible studies were required to meet the following inclusion criteria: (i) investigating the association between CTLA-4 rs231775 and acute rejection (AR) in kidney transplant recipients (KTRs) (ii) reporting sufficient data for estimating an odds ratio (OR) with 95\% confidence interval (CI) for the association with CTLA-4 rs231775. Exclusion criteria were: not human studies or not related to the research topics; case reports, editorials and meeting abstracts; narrative reviews, systematic reviews with or without meta-analysis; duplication of previous publications. The potentially relevant articles were then read in their entirety to assess their appropriateness for inclusion in the systematic review. Reference lists of retrieved studies were also checked to identify other potentially eligible studies. If two or more studies shared part of the same patients’ population, the one with the larger sample size or more complete data was included. The corresponding authors were contacted by e-mail when the eligible paper had insufficient information for calculation of OR and 95\% CI. Studies were excluded if the corresponding author did not answer to the e-mail or was unable to provide the requested data.

Data extraction and study quality assessment. From each identified study the following data were extracted: name of first author; year of publication; study location; ethnicity; mean age; male/female ratio; donor type (i.e. living or deceased); immunosuppressive drugs; criteria for diagnosis of acute rejection; number of KTRs with and without AR; timing of AR after kidney transplantation; method of CTLA-4 rs231775 genotyping, and allele/genotype counts. Methodological study quality was assessed using the Newcastle–Ottawa scale (NOS) for cohort studies (available at: https://www.ohri.ca/programs/clinical-epidemiology/oxford.asp), which consists of three components: (I) selection and definition of the study groups (0–4 points); (II) comparability of the cohorts (0–2 points); and (III) ascertainment of outcomes (0–3 points). Studies with a NOS score ≥ 7 out of 9 were considered of higher quality. All studies were independently analyzed by two reviewers (S.T. and S.C.) and any discrepancies in study selection, data extraction and methodological quality evaluation were resolved through consensus.

Data synthesis and analysis. For each study, the Hardy–Weinberg Equilibrium (HWE) was calculated using the Pearson’s goodness-of-fit chi-square test implemented in the online Finetti’s program (available at https://ihg.gsdf.de/cgi-bin/hw/hwa1.pl). ORs were pooled based on the allelic (G vs. A), dominant (GG/AG vs. AA) or recessive (GG vs. AG/AA) genetic contrast of CTLA-4 rs231775 by using the random-effects (DerSimonian–Laird method) model, which takes into account both within study variance and cross-study variance\textsuperscript{32}. In case of lack of heterogeneity, the random effects model coincides with the fixed-effect model\textsuperscript{33}. Between-study heterogeneity was tested using the Q statistic, with a p-value < 0.10 indicating the presence of significant heterogeneity. Heterogeneity was also quantified by the I\textsuperscript{2} metric, with I\textsuperscript{2} values > 50\% indicating heterogeneity among studies. Heterogeneity was again quantified by the I\textsuperscript{2} metric, with I\textsuperscript{2} values > 50\% indicating high heterogeneity\textsuperscript{34}. The robustness of overall estimates was verified by conducting subgroup and sensitivity analyses. The presence of publication bias or a difference between small and large studies (‘small-study effects’) in the overall analyses was evaluated graphically by drawing funnel plots and statistically by means of Egger’s test\textsuperscript{35}. In case of statistical evidence of funnel plot asymmetry (P-value of the Egger’s test < 0.10), the ‘trim-and-fill’ method was used to adjust the overall pooled estimate for potential publication size or small study effects\textsuperscript{36}. All analyses were performed using ProMeta software (version 2; Internovoi di Scarpellini, Daniele SAS, Cesena, Italy) and the significance of pooled ORs was set at P < 0.05. Noteworthiness of significant pooled ORs was also estimated by false positive report probability (FPRP)\textsuperscript{37}, which is calculated based on the statistical power of the test, the observed P-value, and a given prior probability for the association. FPRP values were calculated at the prior probability of 0.001 (expected for a candidate gene)\textsuperscript{38} to detect ORs of 1.50 (or its reciprocal 1/1.5 = 0.67), by using the Excel spreadsheet provided by Wacholder et al.\textsuperscript{39}. A significant result (P < 0.05) with an FPRP value of less than 0.2 indicated a noteworthy association.

Trial sequential analysis. Trial sequential analysis (TSA) allows to control the risk of type I (false positive) and type II (false negative) errors of conventional meta-analysis and to calculate the required information size (RIS), that is the required number of participants in a reliable and conclusive meta-analysis\textsuperscript{27}. We estimated the RIS based on an overall 5\% risk of a type I error (two sided a = 0.05), a statistical test power of 80\% (β = 0.2) and an “a priori” relative risk difference (reduction or increase) of 15\%. In addition, we set the event proportion in the reference genotype or allele group as the median value across studies included in the meta-analysis, and we adjusted the required information size for study heterogeneity by applying a D\textsuperscript{2} adjustment factor\textsuperscript{39}. If the cumulative Z curve crosses the trial sequential monitoring boundaries with achievement of RIS, it means that a
sufficient level of evidence has been reached and further studies are unneeded. When the Z curve does not cross any of the boundaries and the RIS has not been reached, it can be concluded that more studies are required to reach a sufficient conclusion. If the cumulative Z curve crosses the futility boundaries, the conclusion of indiscrimination between two groups is accepted under the given conditions. TSA was performed using Trial Sequential Analysis software version 0.9.5.10 beta (available at www.ctu.dk/tsa).

Results

Literature screening process and characteristics of the identified studies. The flow chart illustrating the overall literature selection process is illustrated in Fig. 1. Briefly, the literature search on PubMed, Web of Knowledge, Cochrane Library and Open Grey resulted in a total of 151 citations. After removing of 50 duplicated records, the remaining 101 studies were evaluated by carefully reading of titles, abstracts and full texts. After exclusion of additional 87 not relevant papers, 14 studies describing a total of 15 cohorts were included in the systematic review of association between CTLA-4 rs231775 and risk of acute renal graft rejection. The main characteristics of the identified studies are summarized in Table 1. In brief, studies were published between 2005 and 2019, mean age ranged from 30 to 49.6 years, and sample size varied from 63 to 2,872. The most represented ethnic populations were Caucasian, Asian and African, which were included, respectively, in eight, three and two studies. The largest study included a cohort of European Americans (n = 2,390) and a cohort of African Americans (n = 482). In the majority of the identified studies, patients received renal allografts from living or cadaveric donors, while in 4 studies the transplanted kidney came exclusively from a cadaveric donor.

CTLA-4 rs231775 was found in Hardy–Weinberg equilibrium (HWE) in 9 studies; it significantly deviated from HWE in three studies, which reported genotype data as a combined group (AG/AA vs. GG). The distribution of CTLA-4 rs231775 genotypes for each included cohort and timing of AR assessment after kidney transplantation is shown in Table 2. Other study characteristics, including immunosuppressive drugs, criteria used for acute rejection diagnosis, and the genotyping method of CTLA-4 rs231775 are reported in Supplementary Material, Table S1. With regard to the study quality, the overall NOS scores ranged from 3 to 9 (median 7) (Table 1). Ten studies with a NOS score ≥ 7 were considered of higher quality. Individual scores for each item of NOS in the identified studies are shown in Supplementary Material, Table S2.

Quantitative data synthesis. A total of 15 cohorts including 5,401 KTRs were available for the meta-analysis of CTLA-4 rs231775 under the recessive contrast model (GG vs. AG/AA), while 13 cohorts enrolling 4,443 KTRs were available for the allelic (G vs. A) or the dominant (GG/AG vs. AA) model. A summary of random meta-analyses on the effect of CTLA-4 rs231775 on the risk of acute renal graft rejection is shown in Table 3. The pooled results showed no association with the allelic (G vs. A, OR 1.07, 95% CI 0.88–1.30, P = 0.49;
Table 1. Characteristics of studies included in the meta-analysis of association between CTLA-4 rs231775 and acute renal allograft rejection. AA subgroup of African Americans; AR acute rejection group; EA subgroup of European Americans; HWE Hardy–Weinberg Equilibrium; KT kidney transplantation; NAR no acute rejection group; NOS Newcastle–Ottawa scale.

| First author  | Year | Location (ethnicity) | Case number (AR/NAR) | Age (year, mean ± SD/range) | Male/female | Donor type (living/deceased) | Timing of AR after KT | P-value for HWE | NOS score |
|---------------|------|----------------------|----------------------|----------------------------|-------------|-----------------------------|-----------------------|---------------|-----------|
| Dmitrienko    | 2005 | Canada (Caucasian)   | 100 (50/50)          | 44 ± 10.5                  | 57/43       | 40/59                       | ≤ 1 year              | 0.04          | 8         |
| Gendzekhadze  | 2006 | Venezuela (Latino)   | 63 (30/33)           | 40 ± 10                    | 37/26       | 33/30                       | ≤ 3 months             | 0.51          | 6         |
| Gorgi         | 2006 | Tunisia (African)    | 70 (31/39)           | 30 (12–56)                 | 44/26       | –                           | –                     | 0.18          | 3         |
| Wiśniewski    | 2006 | Poland (Caucasian)   | 91 (38/53)           | –                          | –           | –                           | ≥ 6 months             | 0.06          | 6         |
| Haimila       | 2009 | Finland (Caucasian)  | 678 (109/535)        | 49.6 (17.8–74.5)           | 430/248     | 0/678                       | –                     | NC            | 8         |
| Kim           | 2010 | Korea (Asian)        | 325 (59/266)         | 40.1 ± 11.4                | 198/127     | –                           | ≤ 6 months             | 0.56          | 8         |
| Kuśtala       | 2010 | Poland (Caucasian)   | 314 (102/212)        | 41.9 ± 12.1                | 184/130     | 2/312                       | ≤ 5 years              | NC            | 7         |
| Domanski      | 2012 | Poland (Caucasian)   | 269 (70/199)         | 47.6 ± 13.0                | 166/103     | 0/269                       | ≤ 5 years              | 0.30          | 7         |
| Gao           | 2012 | China (Asian)        | 167 (45/122)         | 46.8 ± 11.3                | 105/62      | 0/167                       | ≤ 6 months             | 0.77          | 8         |
| Canossi       | 2013 | Italy (Caucasian)    | 72 (37/35)           | –                          | –           | 0/72                        | ≤ 6 months             | 0.67          | 4         |
| Mirza         | 2014 | India (Asian)        | 190 (36/154)         | –                          | –           | –                           | ≤ 3 months             | 0.006         | 7         |
| Ruhi          | 2015 | Turkey (Caucasian)   | 81 (34/47)           | 35.8 ± 11.7                | 62/19       | 81/0                        | ≤ 6 months             | 0.74          | 8         |
| Niknam        | 2017 | Iran (Iranian)       | 172 (45/127)         | 38.3 ± 14.3                | 113/59      | 73/99                       | ≤ 3 months             | 0.02          | 7         |
| Oetting       | 2019 | USA (European Americans) | 2,390 (421/1699)   | 50.4 ± 14.7                | 1,500/890   | 1617/773                    | > 12 months            | 0.84          | 9         |
|               |      | (African Americans)  | 482 (71/411)         | 46.9 ± 12.2                | 303/179     | 155/327                     | ≤ 12 months            | 0.35          | 9         |

Table 2. Distribution of CTLA-4 rs231775 among the 15 identified cohorts. AR acute rejection group; KT kidney transplantation; M months; NAR no acute rejection group; Y year.
Fig. 2A), dominant (GG/AG vs. AA, OR 0.94, 95% CI 0.73–1.22, P = 0.66; Fig. 3A) or the recessive genetic model (GG vs. AG/AA, OR 1.18, 95% CI 0.97–1.43, P = 0.096; Fig. 4A). The TSA for the allelic (Fig. 2B) or the dominant (Fig. 3B) model showed that the cumulative Z-curve (blue line) crossed neither the trial sequential monitoring boundaries (red inward slash), nor the conventional boundaries (black dotted line); however, it entered the futility area without reaching the required information size (G vs. A, RIS = 11,247; GG/AG vs. AA, RIS = 8,475). For the recessive model contrast (GG vs. AG/AA, Fig. 4B), the cumulative Z-curve crossed the futility boundary and reached the required information size (RIS = 4,804).

Publication bias. In overall analyses, no evidence of publication bias or small study effects was found for the GG/AG vs. AA model (Egger’s P-value = 0.14, Fig. 5B) and the GG vs. AG/AA model (Egger’s P-value = 0.16, Fig. 5C). Conversely, a statistically significant funnel plot asymmetry was detected for the G vs. A model (Egger’s P-value = 0.045, Fig. 5A). The trim-and-fill method for the allelic contrast model (G vs. A) imputed three missing studies on the left side of the funnel plot (Fig. 5D), however the adjusted effect size was still not significant (OR 0.95; 95% CI 0.78–1.15, P = 0.57).

Subgroup and sensitivity analyses. The Q-statistic indicated the presence of between-study heterogeneity in the meta-analysis for the allelic (P = 0.014, I² = 52%) and dominant (P = 0.060, I² = 41%) models (Table 3), but not for the recessive model contrast (P = 0.33, I² = 11%). In order to explore possible reasons for the observed heterogeneity, we conducted a subgroup analysis stratified by ethnicity, as well as three sensitivity analyses by using the following inclusion criteria: higher study quality (NOS ≥ 7), conformation with HWE, and AR within one year after kidney transplantation. A significant association was detected among Asians for the allelic (G vs. A, OR 1.55, 95% CI 1.16–2.07, P = 0.003) or the recessive model contrast (GG vs. AG/AA, 1.93, 95% CI 1.31–2.86, P = 0.001) in absence of between-study heterogeneity (I² = 0%), while no association with CTLA-4 rs231775 was found among Caucasian or African patients. Results of sensitivity analyses provided evidence of a higher risk of acute rejection in the first year after kidney transplantation among carriers of the rs231775GG genotype (OR 1.37, 95% CI 1.00–1.88, P = 0.048), while no associations were detected among studies conforming to HWE or with a higher quality score (NOS ≥ 7) (Table 3).

| Group or subgroup | No of cohorts | AR/NAR (genotypes or alleles) | Test of association | Test of heterogeneity | Egger’s P-value | FPRP value at prior probability of 0.001 | Power* | OR = 1.5 |
|-------------------|--------------|-------------------------------|--------------------|-----------------------|-----------------|----------------------------------------|--------|----------|
| G vs. A           | Overall      | 13 1928/6,958                 | 1.07 (0.88–1.30)   | 0.49                  | 52              | 0.014                                  | 0.045  |          |
|                   | Caucasian    | 6 1,294/4,664                 | 0.93 (0.77–1.12)   | 0.47                  | 19              | 0.47                                   |        |          |
|                   | Asian        | 3 280/1,084                   | 1.55 (1.16–2.07)   | 0.003                 | 0               | 0.62                                   | 0.412  | 0.879    |
|                   | African      | 2 204/890                    | 0.73 (0.46–1.15)   | 0.17                  | 33              | 0.22                                   |        |          |
|                   | HWE          | 10 1666/6,296                | 1.02 (0.83–1.26)   | 0.89                  | 51              | 0.030                                  |        |          |
|                   | NOS ≥ 7      | 9 1662/6,640                 | 1.10 (0.89–1.36)   | 0.39                  | 58              | 0.016                                  |        |          |
|                   | AR during the first year after KT | 7 1,214/6,038 | 1.17 (0.89–1.55) | 0.26                  | 63              | 0.013                                  |        |          |
| GG/AG vs. AA      | Overall      | 13 964/3,479                 | 0.94 (0.73–1.22)   | 0.66                  | 41              | 0.080                                  | 0.14   |          |
|                   | Caucasian    | 6 647/2,332                  | 0.87 (0.63–1.20)   | 0.40                  | 36              | 0.16                                   |        |          |
|                   | Asian        | 3 140/542                    | 1.38 (0.82–2.32)   | 0.22                  | 0               | 0.71                                   |        |          |
|                   | African      | 2 102/445                    | 0.47 (0.13–1.80)   | 0.27                  | 62              | 0.10                                   |        |          |
|                   | HWE          | 10 833/3,148                 | 0.87 (0.65–1.16)   | 0.35                  | 38              | 0.10                                   |        |          |
|                   | NOS ≥ 7      | 9 831/3,320                  | 0.92 (0.73–1.17)   | 0.50                  | 26              | 0.21                                   |        |          |
|                   | AR during the first year after KT | 8 652/3,141 | 1.13 (0.78–1.65) | 0.51                  | 57              | 0.024                                  |        |          |
| GG vs. AG/AA      | Overall      | 15 1,175/4,226               | 1.18 (0.97–1.43)   | 0.096                 | 11              | 0.33                                   | 0.16   |          |
|                   | Caucasian    | 8 858/3,079                  | 1.04 (0.85–1.28)   | 0.69                  | 0               | 0.66                                   |        |          |
|                   | Asian        | 3 140/542                    | 1.93 (1.31–2.86)   | 0.001                 | 0               | 0.57                                   | 0.105  | 0.909    |
|                   | African      | 2 102/445                    | 0.79 (0.45–1.38)   | 0.40                  | 0               | 0.59                                   |        |          |
|                   | HWE          | 10 833/3,148                 | 1.16 (0.89–1.51)   | 0.26                  | 21              | 0.25                                   |        |          |
|                   | NOS ≥ 7      | 11 1,042/4,067               | 1.19 (0.96–1.48)   | 0.11                  | 20              | 0.25                                   |        |          |
|                   | AR during the first year after KT | 8 652/3,141 | 1.37 (1.00–1.88) | 0.048                 | 30              | 0.19                                   | 0.706  | 0.985    |

Table 3. Summary of random-effect meta-analyses for the relationship between CTLA-4 rs231775 and acute renal graft rejection. AR acute rejection group; HWE Hardy–Weinberg equilibrium; KT kidney transplantation; NAR no acute rejection group; NOS Newcastle–Ottawa scale. *Power to detect a noteworthy finding by false positive report probability (FPRP) when the true OR equals the specified value.
FPRP analysis. Statistically significant findings (P < 0.05) of subgroup and sensitivity analyses were further investigated by using the FPRP test. At the pre-specified prior probability level of 0.001 to detect ORs of 1.50 (or its reciprocal 1/1.5 = 0.67), the FPRP values for the association of rs231775G or rs231775GG among Asians were 0.879 and 0.909, respectively, while the FPRP value for the association of rs231775GG with AR in the first year after kidney transplantation was 0.985 (Table 3). Therefore, none of these associations was found noteworthy under FPRP (cutoff value < 0.2), indicating no reliable results. Similarly, analysis of significant genetic comparisons of previous meta-analyses on the association of CTLA-4 rs231775 and acute renal transplant rejection revealed FPRP values higher than 0.2, indicating lack of noteworthy results (Table 4).
Discussion

In the two most recent meta-analyses, a higher risk of acute rejection has been reported in kidney transplant recipients under the GG vs AA/AG model of CTLA-4 rs231775, but only the larger study also detected a higher risk under the G vs. A model contrast. Given the recent publication of two novel primary studies on the risk of acute kidney transplant rejection, we conducted an updated meta-analysis with trial sequential analysis (TSA) to better estimate the impact of CTLA-4 rs231775 and to determine whether the currently available evidence was sufficient and conclusive. In addition, false-positive report probability (FPRP) analysis was conducted to examine whether the significant findings of the present or previous meta-analyses were noteworthy. To our knowledge, Dong and colleagues, in 2008, first applied FPRP to assess noteworthiness of meta-analytic estimates in a field synopsis. Since then, more than 40 meta-analyses of genetic association studies have been published in which the FPRP method was applied to examine noteworthiness of significant pooled estimates.

Figure 3. Forest plot (A) and TSA (B) for the association between the dominant (GG + AG vs AA) genetic model of CTLA-4 rs231775 and acute renal graft rejection. ES effect size (i.e. odd ratio); W weight; Sig statistical significance; N total number of kidney transplant recipients; N1 number of patients with GG or AG genotype; N2 number of patients with AA genotype. The required information size (RIS) was calculated based on a two side α = 5%, β = 20% (power 80%), and an “a priori” relative risk reduction of 15%. 
This updated systematic review and meta-analysis, which included a total of 5,401 kidney transplant recipients, showed that CTLA-4 rs231775 is not a genetic determinant of acute rejection. Results from the traditional pooled analysis technique are corroborated by TSA, which provided conclusive evidence against a clinically relevant impact of CTLA-4 rs231775 on the risk of acute renal graft rejection under the allelic (G vs A), dominant (GG/AG vs AA) or the recessive model (GG vs AG/AA). Furthermore, none of the positive findings detected in the subsequent subgroup and sensitivity analyses, such as association of the G allele or of the GG genotype with a higher risk in Asian KTRs, were found to be noteworthy by FPRP. Similarly, the application of the FPRP test to statistically significant results of previously published meta-analyses also revealed a lack of noteworthy results in the relationship between CTLA-4 rs231775 and acute renal transplant rejection. Overall, the current

Figure 4. Forest plot (A) and TSA (B) for the association between the recessive (GG vs AG + AA) genetic model of CTLA-4 rs231775 and acute renal graft rejection. ES, effect size (i.e. odd ratio); W, weight; Sig, statistical significance; N, total number of kidney transplant recipients; N1, number of patients with GG genotype; N2, number of patients with AG or AA genotype. The required information size (RIS) was calculated based on a two side α = 5%, β = 20% (power 80%), and an “a priori” relative risk increase of 15%.
findings confute results of the most recent and larger meta-analysis25, which however included only 2,581 kidney transplant recipients.

As a key regulator of the immune response magnitude, CTLA-4 genetic variation has been placed at the center of attention by investigators also for a possible role in autoimmunity48 and cancer49. Results from traditional meta-analyses show that the GG genotype of rs231775, which is associated to lower CTLA-4 expression and hence to a higher T cell activation and proliferation, may confer susceptibility to development of autoimmune diseases, such as rheumatoid arthritis50, Hashimoto’s thyroiditis51 and myasthenia gravis52. On the other hand, individuals with higher expression of membrane CTLA-4, due to the rs231775 A allele, may be at risk of developing multiple types of cancer53. These and other evidence support the hypothesis that only an optimal CTLA-4 expression can ensure a state of self-tolerance54, being rs231775 G (the low-activity allele) and rs231775 A (the high-activity allele) of CTLA-4 associated, respectively, with susceptibility to autoimmunity and cancer. However, the relevance of CTLA-4 rs231775 has not been consistently reported in every disease condition and is even less pronounced in cancer than in autoimmune diseases54. Interestingly, a meta-analysis with TSA have provided convincing evidence for association of CTLA-4 rs231775 with Hashimoto’s thyroiditis55, nevertheless further investigation is still needed to clarify the role of CTLA-4 rs231775 in different autoimmune disorders and cancer types. In this regard, future application of TSA and/or FPRP to updated meta-analyses could be of value for conclusive demonstration of CTLA-4 rs231775 as susceptibility risk factor for autoimmunity and cancer.

Despite strengths of the present meta-analysis, such as the use of TSA and FPRP, our findings should be interpreted in the light of the following limitations and considerations. First, we attempted to conduct a comprehensive systematic review to identify all potential relevant articles, nevertheless corresponding authors of some eligible publications were unable, or unavailable, to provide genotype distribution of CTLA-4 rs231775.
Table 4. Significant genetic comparisons from previous meta-analyses evaluating the association between CTLA-4 rs231775 and acute renal graft rejection: results of the FPRP test. F Fixed-effect model, NR not reported. *NC, not calculable because of less than two studies. **NC, not calculable because of less than three studies. *Power to detect a noteworthy finding by false positive report probability (FPRP) when the true OR equals the specified value.

Among these, corresponding authors of two genome-wide association studies (GWAS)\(^{56,57}\), reporting no evidence of association between CTLA-4 rs231775 and acute renal graft rejection, were unavailable to provide genotypes for the rs231775 SNP. Therefore, our pooled estimates must be interpreted with caution given the lack of inclusion of all available studies in the meta-analysis. Nevertheless, our TSA results showed that sufficient cumulative evidence has been reached to conclusively exclude a clinically relevant association of the G allele or GG genotype of CTLA-4 rs231775 with a higher risk of acute renal graft rejection. Second, it should be noted that a funnel plot asymmetry, indicating potential publication bias, was indeed detected for the allelic model (G vs. A), which however included only 13 cohorts compared to the 15 cohorts available for the recessive model (GG vs. AG/AA). In spite of this, the statistical correction for this bias, by using the trim and fill method, confirmed the combined risk estimate towards a null effect. Third, the majority of KTRs comprised in the present meta-analysis was of Caucasian ancestry (3,937 out of 5,401), therefore a clinically relevant impact of CTLA-4 rs231775 in other ethnic groups cannot be formally excluded. Fourth, given the large heterogeneity among studies in terms of immunosuppressive therapy, we were unable to evaluate the impact of rs231775 on the risk of acute renal rejection according to a specific immunosuppressive drug. Fifth, we cannot exclude that CTLA-4 polymorphic variants other than rs231775 might play a role as genetic predictive factors for acute renal rejection. In this regard, it should be noted that a number of meta-analyses have been published on the association between other polymorphisms of CTLA-4 and acute renal rejection\(^{20-22,58,59}\), however none of these studies applied TSA or FPRP for convincing evidence of an association between these additional CTLA-4 SNPs and acute renal allograft rejection. Finally, the lack of informative data in the identified studies precluded the possibility to adjust ORs for clinical confounding factors, and to investigate interaction effects of rs231775 with other polymorphic gene variants of CTLA-4.

In summary, findings of this systematic review and meta-analysis exclude a role of CTLA-4 rs231775 as a genetic risk factor for acute renal transplant rejection. This conclusion is strengthened by results of TSA, which provided conclusive evidence against a clinically relevant impact of CTLA-4 rs231775 on the risk of acute renal graft rejection in overall populations. Nevertheless, large studies comprising Asian or African kidney transplant recipients are still required to clarify the impact of CTLA-4 rs231775 on acute rejection risk in non-Caucasian populations. In addition, investigation is also warranted in kidney transplant recipients to evaluate whether CTLA-4 rs231775 may have an effect on the risk of acute rejection when analyzed in combination with other CTLA-4 gene variants.

Received: 20 January 2020; Accepted: 21 July 2020
Published online: 30 July 2020

References
1. Walunas, T. L. et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1, 405–413 (1994).
2. Masteller, E. L., Chuang, E., Mullen, A. C., Reiner, S. L. & Thompson, C. B. Structural analysis of CTLA-4 function in vivo. J. Immunol. 164, 5319–5327 (2000).
3. Chikuma, S., Imboden, J. B. & Bluestone, J. A. Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 197, 129–135 (2003).
4. Clarkson, M. R. & Sayegh, M. H. T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation 80, 555–563 (2005).
5. Kittai, A. S., Oldham, H., Cetnar, J. & Taylor, M. Immune checkpoint inhibitors in organ transplant patients. *J. Immunother.* 40, 277–281 (2017).

6. Slavcheva, E. et al. Cytotoxic T-lymphocyte antigen 4 gene polymorphisms and susceptibility to acute allograft rejection. *Transplantation* 72, 935–940 (2001).

7. Marder, B. A. et al. The impact of costimulatory molecule gene polymorphisms on clinical outcomes in liver transplantation. *Am. J. Transplant.* 3, 424–431 (2003).

8. Tapirdamaz, O. et al. Polymorphisms in the T cell regulatory gene cytotoxic T lymphocyte antigen 4 influence the rate of acute rejection after liver transplantation. *Gut* 55, 863–868 (2006).

9. Yang, C. H. et al. Relationship between cytotoxic T-lymphocyte antigen 4–318C/T (rs5742909) gene polymorphism and the risk of acute rejection in renal transplantation. *Pediatr. Transplant.* 21, e12920. https://doi.org/10.1111/petr.12920 (2017).

10. Brunet, J. F. et al. A new member of the immunoglobulin superfamily — CTLA-4. *Nature* 328, 267–270 (1987).

11. Dariavach, P., Mattéi, M. G., Golstein, P. & Lefranc, M. P. Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. *Eur. J. Immunol.* 18, 1901–1905 (1988).

12. Ligers, A., Teleshova, N., Masterman, T., Huang, W. X. & Hillert, J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. *Genes Immun.* 2, 145–152 (2001).

13. Haimila, K. et al. Association of genetic variation in inducible costimulator gene with outcome of kidney transplantation. *Transplantation* 87, 393–396 (2009).

14. Domänski, L. et al. The impact of rs231775 (+49AG) CTLA4 gene polymorphism on transplanted kidney function. *Ann. Transplant.* 17, 29–35 (2012).

15. Gao, J. W. et al. Polymorphisms in cytotoxic T lymphocyte associated antigen 4 influence the rate of acute rejection after renal transplantation in 167 Chinese recipients. *Transpl. Immunol.* 26, 207–211 (2012).

16. Misra, M. K., Kapoor, R., Pandey, S. K., Sharma, R. K. & Agrawal, S. Association of CTLA-4 gene polymorphism with end-stage renal disease and renal allograft outcome. *J. Interferon Cytokine Res.* 34, 148–161 (2014).

17. Gendzekhadze, K., Rivas-Vetencourt, P. & Montano, R. F. Risk of adverse post-transplant events after kidney allograft transplantation as predicted by CTLA-4 +49 and TNF-alpha -308 single nucleotide polymorphisms: a preliminary study. *Transpl. Immunol.* 16, 194–199 (2006).

18. Canossi, A. et al. Influence of cytotoxic T-lymphocyte antigen-4 polymorphisms on acute rejection onset of cadaveric renal transplants. *Transplant. Proc.* 45, 2645–2649 (2013).

19. Ruhí, Ç, Sallakçi, N., Y eğin, O., Süleymanlar, G. & Ersoy, F. F. The influence of CTLA-4 single nucleotide polymorphisms on acute kidney allograft rejection in Turkish patients. *Clin. Transplant.* 29, 612–618 (2015).

20. Zhu, C. L., Huang, Q., Liu, C. H. & Xie, F. Polymorphisms in the cytotoxic T-lymphocyte antigen 4 gene and acute rejection risk in transplant recipients. *Med. Biol. Res.* 39, 8701–8708 (2012).

21. Duan, Z. et al. Association between CTLA4 gene polymorphisms and acute rejection of kidney transplantation: a meta-analysis. *J. Nephrol.* 25, 996–1002 (2012).

22. Han, F. et al. Association between co-stimulatory molecule gene polymorphism and acute rejection of allograft. *Transpl. Immunol.* 31, 81–86 (2014).

23. Gao, J. W., Zhou, Z. H., Guo, S. C., Guo, Y. F. & Guo, F. A deeper understanding of the association between CTLA4 +49A/G and acute rejection in renal transplantation: an updated analysis. *Ren. Fail.* 37, 165–174 (2015).

24. Liu, K. et al. Impact of inducible co-stimulator gene polymorphisms on acute rejection on renal transplant recipients: An updated systematic review and meta-analysis. *Meta Gene* 12, 118–124 (2017).

25. Yang, C. H. et al. Association of cytotoxic T-lymphocyte antigen 4 +49A/G gene polymorphism with acute rejection risk in renal transplantation. *Pediatr. Transplant.* 21, e12916. https://doi.org/10.1111/petr.12916 (2017).

26. Watterslev, J., Thorlund, K., Brok, J. & Glud, C. Trial sequential analysis may establish when firm evidence is reached in cumulativa meta-analysis. *J. Clin. Epidemiol.* 61, 64–75 (2008).

27. Brok, J., Thorlund, K., Glaud, C. & Watterslev, J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. *J. Clin. Epidemiol.* 61, 763–769 (2008).

28. Shah, A. & Smith, A. F. Trial sequential analysis: adding a new dimension to meta-analysis. *Anasth.esia* 75, 15–20 (2020).

29. Niknam, A. et al. Polymorphisms of the costimulatory genes CTLA-4, CD28, PD-1, and ICOS and outcome of kidney transplants in Iranian patients. *Exp. Clin. Transplant.* 15, 295–305 (2017).

30. Oeting, W. S. et al. Analysis of 75 candidate SNPs associated with acute rejection in kidney transplant recipients: validation of rs2910164 in microRNA MIR146A. *Transplantation* 103, 1391–1602 (2019).

31. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* 6, e1000979. https://doi.org/10.1371/journal.pmed.1000979 (2009).

32. Furukawa, T. A., Guyatt, G. H. & Griffith, L. E. Can we individualize the number needed to treat? An empirical study of summary effect measures in meta-analyses. *Int. J. Epidemiol.* 31, 72–76 (2002).

33. Zintzaras, E. & Lau, J. Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. *J. Clin. Epidemiol.* 61, 634–645 (2008).

34. Higgin, B. & Thompson, S. G., Deeks, J. J. & Altman, D. G. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. *J. Natl. Cancer Inst.* 96, 1344–442 (2004).

35. Thomas, D. C. & Clayton, D. G. Betting odds and genetic associations. *Br. Med. J.* 335, 56–58 (2006).

36. Duval, S. & Tweedie, R. Trim and fill: a simple funnel-plot based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 56, 455–463 (2000).

37. Wacholder, S., Channock, S., Garcia-Closas, M., El Ghormli, L. & Rothman, N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. *J. Natl. Cancer Inst.* 96, 434–442 (2004).

38. Thomas, D. C. & Clayton, D. G. Betting odds and genetic associations. *J. Natl. Cancer Inst.* 96, 421–423 (2004).

39. Watterslev, J., Thorlund, K., Brok, J. & Glud, C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. *BMC Med. Res. Methodol.* 9, 86. https://doi.org/10.1186/1471-2288-9-86 (2009).

40. Brok, J., Thorlund, K., Watterslev, J. & Glud, C.Apparently conclusive meta-analyses may be inconclusive—Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. *Int. J. Epidemiol.* 38, 287–298 (2009).

41. Thorlund, K. et al. User manual for trial sequential analysis (TSA) 1–115 (Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark, 2011). https://ctu.dk/tsa.

42. Dmitrienko, S., Hoar, D. I., Balshaw, R. & Keown, P. A. Immune response gene polymorphisms in renal transplant recipients. *Transplantation* 80, 1773–1782 (2005).

43. Gorgi, Y. et al. CTLA-4 exon 1 (+49) and promoter (-318) gene polymorphisms in kidney transplantation. *Transplant. Proc.* 38, 2303–2305 (2006).

44. Wisniewski, A. et al. Possible association of cytotoxic T-lymphocyte antigen 4 gene promoter single nucleotide polymorphism with acute rejection of allogeneic kidney transplant. *Transplant. Proc.* 38, 56–58 (2006).

45. Kim, H. J. et al. Polymorphisms of the CTLA4 gene and kidney transplant rejection in Korean patients. *Transpl. Immunol.* 24, 40–44 (2010).
46. Kusztal, M. et al. The influence of CTLA-4 gene polymorphism on long-term kidney allograft function in Caucasian recipients. *Transpl. Immunol.* **23**, 121–124 (2010).

47. Dong, L. M. et al. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. *JAMA* **299**, 2423–2436 (2008).

48. Ueda, H. et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. *Nature* **423**, 506–511 (2003).

49. Sun, T. et al. Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. *Cancer Res.* **68**, 7025–7034 (2008).

50. Li, G., Shi, F., Liu, J. & Li, Y. The effect of CTLA-4 A49G polymorphism on rheumatoid arthritis risk: a meta-analysis. *Diagn. Pathol.* **9**, 157. https://doi.org/10.1186/s13000-014-0157-0 (2014).

51. Qiu, H., Tang, W., Yin, P., Cheng, F. & Wang, L. Cytotoxic T-lymphocyte associated antigen 4 polymorphism and Hashimoto's thyroiditis susceptibility: a meta-analysis. *Endocrine* **45**, 198–205 (2014).

52. Li, F., Yuan, W. & Wu, X. Association of CTLA-4 polymorphisms with increased risks of myasthenia gravis. *Ann. Hum. Genet.* **82**, 358–369 (2018).

53. Fang, M., Huang, W., Mo, D., Zhao, W. & Huang, R. Association of five SNPs in cytotoxic t-lymphocyte antigen 4 and cancer susceptibility: evidence from 67 studies. *Cell Physiol. Biochem.* **47**, 414–427 (2018).

54. Ghaderi, A. CTLA4 gene variants in autoimmunity and cancer: a comparative review. *Iran J. Immunol.* **8**, 127–149 (2011).

55. Hu, Y. et al. Associations between three CTLA-4 polymorphisms and Hashimoto's thyroiditis risk: an updated meta-analysis with trial sequential analysis. *Genet. Test Mol. Biomark.* **22**, 224–236 (2018).

56. Ghisdal, L. et al. Genome-wide association study of acute renal graft rejection. *Am. J. Transplant.* **17**, 201–209 (2017).

57. Hernandez-Fuentes, M. P. et al. Long- and short-term outcomes in renal allografts with deceased donors: a large recipient and donor genome-wide association study. *Am. J. Transplant.* **18**, 1370–1379 (2018).

58. Yang, C. H. et al. Drummen, G. P. C. Relationship between cytotoxic T-lymphocyte antigen 4–318C/T (rs5742909) gene polymorphism and the risk of acute rejection in renal transplantation. *Pediatr. Transplant.* **21**, 4. https://doi.org/10.1111/petr.12920 (2017).

59. Liu, K. et al. Impact of inducible co-stimulator gene polymorphisms on acute rejection in renal transplant recipients: an updated systematic review and meta-analysis. *Meta Gene.* **12**, 118–124 (2017).

Acknowledgements
The authors thank Dr. William S. Oetting (Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN.) for his kind availability to provide genotype data. S.C. holds a temporary research fellowship (Bando Fondazione CRT, ID 393), supported by University of Piemonte Orientale, which is deeply acknowledged. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author contributions
S.C. and S.T. conceived and designed the study; S.C. and S.T. performed data analysis; S.C., S.T., U.G., J.I.S. wrote the paper. All the authors have read and approved the final version of the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-69849-4.

Correspondence and requests for materials should be addressed to S.T.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020